Drug Approval | June 16, 2023
Briefs: Natco Pharma and Panacea Biotec
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Both products are broad-spectrum, foliar insecticides used across wide range of crops
NATCO estimates the current market size of CTPR containing products in India to be over Rs. 2,000 crore.
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)